26254-07-9

Upstream product

• 30216-01-4 2-phenyl-2-oxazolin-4-one 
• 100-63-0 phenylhydrazine 
• 4461-33-0 benzoyl isocyanate 
• 141-43-5 ethanolamine 
• 588-64-7 benzaldehyde phenylhydrazone 
• 100-52-7 benzaldehyde 

Downstream Products

• 34924-43-1 1,3-diphenyl-1,2,4-triazole 
• 89060-50-4 1,3-diphenyl-1H-1,2,4-triazole-5-carbonitrile 
• 89060-49-1 1,3-Diphenyl-1,2,4-triazol-5-carbaldoxim 
• 89060-65-1 1-(1,3-Diphenyl-1,2,4-triazol-5-yl)ethanol 
• 89060-70-8 1,3-Diphenyl-1,2,4-triazol-5-acrylsaeure 
• 89060-73-1 (2,5-Diphenyl-2H-[1,2,4]triazol-3-yl)-methoxy-methanol 
• 89060-66-2 <2-(1,3-Diphenyl-1,2,4-triazol-5-yl)vinyl>(phenyl)keton 
• 89060-74-2 (2,5-Diphenyl-2H-[1,2,4]triazol-3-yl)-ethoxy-methanol 
• 89060-35-5 4-Dimethylamino-N-<(1,3-diphenyl-1,2,4-triazol-5-yl)methylen>anilin 
• 89060-77-5 (2,5-Diphenyl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl-methanol 
• 89060-78-6 5-Dipiperidinomethyl-1,3-diphenyl-1,2,4-triazol 
• 89060-48-0 1,3-Diphenyl-1,2,4-triazol-5-carbaldehyd-tosylhyrazon 
• 89060-67-3 (1-Cyclohexyl-5-tetrazolyl)(1,3-diphenyl-1,2,4-triazol-5-yl)methanol 
• 87905-22-4 2-(1,3-diphenyl-1H-1,2,4-triazol-5-yl)acetonitrile 

Relevant academic research and scientific papers

1, 3-diaryl-1, 2, 4-triazole compound as well as preparation method and application thereof

The invention discloses a 1, 3-diaryl-1, 2, 4-triazole compound, which has a novel structure shown in a structural general formula I and has better selective inhibition activity on HDAC6. The invention also discloses a preparation method of the compound, aryl groups and 4-amino-N-hydroxy-benzamide groups are introduced to a 1, 2, 4-triazole matrix for modification, a series of compounds with novelstructures are synthesized, and the method has the advantages of mild reaction conditions, simple operation, high yield and the like. The invention also discloses an application of the compound in preparation of a medicine for selectively inhibiting HDAC6. The compound provided by the invention can significantly inhibit HDAC6, the IC50 value of the compound is at a nanomole level, the dosage of apatient is favorably reduced, and the toxic and side effects of the medicine on a human body are reduced. The compound provided by the invention has high selectivity on subtype HDAC1, can effectivelyavoid toxic and side effects of a drug on normal tissues of a human body, and shows good development potential.

Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity

Histone deacetylase 6 (HDAC6) has emerged as a critical regulator of many cellular pathways in tumors due to its unique structure basis and abundant substrate types. Over the past few decades, the role played by HDAC6 inhibitors as anticancer agents has sparked great interest of biochemists worldwide. However, they were less reported for gastric cancer therapy. In this paper, with the help of bioisosteric replacement, in-house library screening, and lead optimization strategies, we designed, synthesized and verified a series of 1,3-diaryl-1,2,4-triazole-capped HDAC6 inhibitors with promising anti-gastric cancer activities. Amongst, compound 9r displayed the best inhibitory activity towards HDAC6 (IC50 = 30.6 nM), with 128-fold selectivity over HDAC1. Further BLI and CETSA assay proved the high affinity of 9r to HDAC6. In addition, 9r could dose-dependently upregulate the levels of acetylated α-tubulin, without significant effect on acetylated histone H3 in MGC803 cells. Besides, 9r exhibited potent antiproliferative effect on MGC803 cells, and promoted apoptosis and suppressed the metastasis without obvious toxicity, suggesting 9r would serve as a potential lead compound for the development of novel therapeutic agents of gastric cancer.

PDE10 MODULATORS

The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.

PDE10 MODULATORS

The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

3-Phenyl-1,2,4-triazole-5-carbaldehydes Substituted in Position 1

The aldehydes 7 - first examples of the yet unknown class of 1,2,4-triazole-5-carbaldehydes substituted in position 1 - can be obtained in excellent yield by lead tetraacetate oxidation of 2; the Kroehnke reaction with 5 provides an alternative route.Due